Explore
← New search
3 matching publication(s)
IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses.
PMID 40128415 · Breast Cancer · 2025
L1
71/100
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · Cell Rep Med · 2024
L1
72/100
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells.
PMID 37231145 · NPJ Precis Oncol · 2023
L1
40/100